Stock listing

NASDAQ:ACTU Actuate Therapeutics, Inc. Stock

Home listing (NASDAQ) of Actuate Therapeutics, Inc.

Follow Actuate Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ACTU

$0.225 USD -0.020 (-8.3%)

Close on Nov 20, 2026

Past year -96.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.200 – $0.248 USDNov 20, 2026
Volume
629,804 sharesNov 20, 2026
Market cap
$13.60M USDAt the close on Nov 20, 2026 · price × 60.38M shares outstanding
52-week range
$0.200 – $7.900 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$429,316 USDMedian day 285,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Actuate Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ACTU · Home$0.225 USD-0.020 (-8.3%)629,804$0.200$0.248$0.200$0.246Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACTU · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.225-0.020-8.3%$0.200$0.248$0.200629,804
$0.246-0.006-2.4%$0.281$0.320$0.24016,133,689
$0.252-0.016-6.1%$0.266$0.295$0.229194,146
$0.268-0.017-6.1%$0.288$0.302$0.255231,014
$0.285-0.011-3.6%$0.332$0.332$0.284173,897
$0.296-0.006-2.1%$0.330$0.350$0.290155,800
$0.302+0.005+1.8%$0.300$0.330$0.30094,578
$0.297-0.017-5.3%$0.318$0.350$0.290174,313
$0.314-0.015-4.6%$0.341$0.350$0.300300,033
$0.329+0.002+0.6%$0.327$0.350$0.301517,894
$0.327-0.043-11.6%$0.355$0.370$0.320479,183
$0.370+0.020+5.7%$0.360$0.380$0.341303,534
$0.350+0.008+2.3%$0.360$0.374$0.338312,301
$0.342+0.007+2.1%$0.380$0.380$0.335295,455
$0.335-0.036-9.7%$0.380$0.385$0.330489,500
$0.371-0.012-3.1%$0.383$0.420$0.360814,000
$0.383-0.017-4.3%$0.404$0.407$0.361715,700
$0.400-0.128-24.2%$0.379$0.438$0.3502,210,500
$0.528+0.053+11.2%$0.507$0.600$0.475236,200
$0.475-0.041-7.9%$0.530$0.556$0.450255,200
$0.516-0.046-8.2%$0.570$0.600$0.470335,000
$0.562-0.054-8.8%$0.598$0.638$0.560220,400
$0.616+0.017+2.8%$0.593$0.662$0.546166,700
$0.599-0.006-1.0%$0.661$0.710$0.520727,300
$0.605+0.105+21.0%$0.493$0.640$0.470926,200
$0.500+0.066+15.2%$0.457$0.550$0.433472,100
$0.434-0.032-6.9%$0.480$0.490$0.410439,400
$0.466-0.178-27.6%$0.660$0.660$0.438967,700
$0.644+0.034+5.6%$0.600$0.680$0.600285,900
$0.610-0.069-10.2%$0.641$0.680$0.610295,000
$0.679-0.045-6.2%$0.682$0.724$0.621324,500
$0.724-0.088-10.8%$0.643$0.724$0.615637,900
$0.812-0.063-7.2%$0.890$0.890$0.760337,700
$0.875+0.056+6.8%$0.850$0.926$0.801201,900
$0.819-0.070-7.9%$0.930$0.950$0.80091,900
$0.889+0.109+14.0%$0.798$0.960$0.765494,100
$0.780+0.094+13.7%$0.710$0.830$0.690409,600
$0.686-0.050-6.8%$0.738$0.748$0.683111,000
$0.736+0.056+8.2%$0.685$0.738$0.604276,900
$0.680+0.060+9.7%$0.650$0.750$0.640382,800
$0.620-0.112-15.3%$0.750$0.750$0.610272,500
$0.732-0.075-9.3%$0.800$0.869$0.720222,000
$0.807-0.100-11.0%$0.900$0.930$0.800187,200
$0.907-0.074-7.5%$0.987$1.020$0.890274,500
$0.981-0.014-1.4%$1.000$1.030$0.960113,100
$0.995-0.002-0.2%$1.040$1.050$0.963174,500
$0.997+0.013+1.3%$1.000$1.050$0.940208,800
$0.984-0.046-4.5%$1.040$1.060$0.980148,400
$1.030-0.040-3.7%$1.080$1.090$0.990259,000
$1.070-0.080-7.0%$1.150$1.230$1.030239,600
$1.150-0.110-8.7%$1.250$1.280$1.130204,400
$1.260-0.110-8.0%$1.380$1.400$1.260119,800
$1.370-0.110-7.4%$1.460$1.480$1.330210,000
$1.480+0.110+8.0%$1.450$1.730$1.3301,322,900
$1.370+0.070+5.4%$1.390$1.460$1.260474,000
$1.300-0.240-15.6%$1.500$1.550$1.300332,300
$1.540+0.020+1.3%$1.490$1.580$1.410129,600
$1.520-0.135-8.2%$1.640$1.650$1.460274,700
$1.655-0.035-2.1%$1.690$1.780$1.630231,300
$1.690-0.090-5.1%$1.770$1.796$1.630366,100
$1.780+0.200+12.7%$1.730$1.970$1.5703,300,900
$1.580+0.350+28.5%$1.240$1.580$1.200589,187
$1.230-0.040-3.1%$1.280$1.310$1.181179,285
$1.270+0.040+3.3%$1.220$1.342$1.180274,700
$1.230+0.170+16.0%$1.060$1.340$1.010939,000
Ticker
NASDAQ:ACTU
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Actuate Therapeutics, Inc. news

Actuate Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 45 in all · newest Nov 18, 2026 · oldest 2024
Decks
16 decks · latest November 2026

Where Actuate Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ACTU · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ACTUBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$11.50M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.75

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Actuate Therapeutics, Inc. · NASDAQ:ACTUUS$13.60MUS$11.50Mn/an/an/an/an/an/a1.75
Citius Pharmaceuticals, Inc. · NASDAQ:CTXRUS$13.96M−US$3.05Mn/an/an/a0.2×n/a0.0×1.71
TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549US$13.68MUS$11.86Mn/an/an/a7.0×n/a0.0×n/a
BeyondSpring, Inc. · NASDAQ:BYSIUS$13.57MUS$12.99M0.3×n/an/a0.9×n/a0.0×1.31
Acumen Pharmaceuticals, Inc. · NASDAQ:ABOSUS$13.49M−US$38.84Mn/an/an/a0.4×n/a0.8×1.45
Pharma Equity Group A/S Class A · OMXCOP:PEGUS$13.47MUS$15.05Mn/an/a52.8×3.6×n/a0.4×n/a
BioInvent International AB · OMXSTO:BINVUS$13.47M−US$6.63Mn/a−1.7×n/a0.7×n/a0.1×n/a
Thalia Therapeutics PLC · LSE:THATUS$13.36MUS$11.39Mn/a1,199×n/a4.2×n/a0.0×n/a
Celyad Oncology SA · EURONEXT:CYADUS$13.31MUS$13.21M14.6×573×n/a9.7×n/a0.0×n/a
Defence Therapeutics Inc Class A · CSE:DTCUS$13.27MUS$13.16Mn/an/an/a5.4×n/a0.5×0.74
Diamyd Medical AB Class B · OMXSTO:DMYD_BUS$13.23M−US$16.68Mn/a−357×n/a0.6×n/a0.0×n/a
Median of the othersUS$13.47MUS$11.63M7.5×286×52.8×2.2×0.0×1.38

Forecasts

3 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
11.68 USD · Analysts' mean
EPS, year to Dec 2026
-0.73 · 3 analysts

Team and board

Officers

OfficerRole
Daniel M. SchmittPresident & Chief Executive Officer

Board

DirectorRole
Aaron G.L. FletcherChairman
Amy RonnebergDirector
Dan ZabrowskiDirector
Daniel M. SchmittPresident & Chief Executive Officer
Jason KeyesDirector
Martin H. HuberDirector
Roger SawhneyDirector
Todd ThomsonDirector

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−6.1%
Q2 2026Aug 14, 2026 · After close−2.0%
Q1 2026May 14, 2026 · After close−9.7%
Q4 2025Mar 31, 2026 · After close−9.1%
Q3 2025Nov 13, 2025 · After close+0.5%
Q2 2025Aug 14, 2025 · After close−1.2%
Q1 2025May 15, 2025 · After close+8.1%
Q4 2024Feb 26, 2025−1.8%
Q3 2024Nov 27, 2024−9.7%
Q2 2024Aug 28, 2024+1.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck16 slidesNovember 2026
Investor Presentation (September 2026)Investor deck17 slidesSeptember 2026
Investor Presentation (May 2026)Investor deck18 slidesMay 11, 2026
Investor Presentation (January 2026)Investor deck34 slidesJanuary 2026
Investor Presentation (November 2025)Investor deck29 slidesNovember 2025
Investor Presentation (August 2025)Investor deck25 slidesAugust 2025
Investor Presentation (May 2025)Investor deck25 slidesMay 31, 2025
Investor Presentation (March 2025)Investor deck21 slidesMarch 2025
Investor Presentation (January 2025)Investor deck21 slidesJanuary 2025
Investor Presentation (December 2024)Investor deck23 slidesDecember 2024
All 16 decks
DeckKindSlidesDate
Investor Presentation (November 2024)Investor deck22 slidesNovember 2024
Investor Presentation (September 2024)Investor deck22 slidesSeptember 2024
IPO Roadshow (July 2024)IPO roadshow27 slidesJul 23, 2024
Investor Presentation (July 2024)Investor deck24 slidesJuly 2024
IPO Roadshow (June 2024)IPO roadshow25 slidesJun 11, 2024
STIFEL 2023 Targeted Oncology DaysConference16 slidesApr 26, 2023

Open Decks

Financings

RaiseDate
Public offering of common stock and warrants
Announced: about US$11M · US$0.71 a share · 1 warrant at US$0.45 for 60 months · Newbridge Securities Corporation
Dealers: Newbridge Securities Corporation (lead)
Use of proceeds: Working capital and general corporate purposes
Oct 27, 2026
Public offering of common stock
Closed: US$17.25M raised · US$7 a share · Lucid Capital Markets +1
Dealers: Lucid Capital Markets (lead), Titan Partners Group, a division of American Capital Partners
Use of proceeds: Working capital and general corporate purposes
Sep 11, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$8.00 a share on Aug 12, 2024.

Price
US$8.00 a share
Shares offered
2,800,000 shares of common stock
Offering size
US$22.4 million
Underwriters' option
Up to 420,000 more shares
Listing
ACTU on the Nasdaq Global Market
Underwriters
Titan Partners Group, Newbridge Securities Corporation · In the order on the cover
Shares delivered
On or about Aug 14, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceMar 4, 2024
Filed publiclyMay 24, 2024
Amended 5 timesNewest Jul 23, 2024
Shares registered with an exchangeJun 20, 2024
Declared effective by the SECAug 12, 2024
Final prospectus, with the priceAug 13, 2024

Filings

FilingFiled
424B4 · ProspectusAug 13, 2024
EFFECT · Notice that a registration is effectiveAug 12, 2024
CERT · Exchange's certificate of listingAug 12, 2024
CORRESP · Letter to the SECAug 12, 2024
CORRESP · Letter to the SECAug 12, 2024
8-A12B/A · Registration of shares for listing on an exchange, amendedAug 12, 2024
CORRESP · Letter to the SECAug 2, 2024
CORRESP · Letter to the SECAug 2, 2024
CORRESP · Letter to the SECJul 30, 2024
CORRESP · Letter to the SECJul 30, 2024
All 46 filings
FilingFiled
CORRESP · Letter to the SECJul 26, 2024
CORRESP · Letter to the SECJul 26, 2024
FWP · Free writing prospectusJul 23, 2024
S-1/A · Registration statement, amendedJul 23, 2024
CORRESP · Letter to the SECJul 19, 2024
CORRESP · Letter to the SECJul 19, 2024
FWP · Free writing prospectusJul 19, 2024
S-1/A · Registration statement, amendedJul 19, 2024
CORRESP · Letter to the SECJul 17, 2024
CORRESP · Letter to the SECJul 17, 2024
S-1/A · Registration statement, amendedJul 16, 2024
CORRESP · Letter to the SECJul 15, 2024
CORRESP · Letter to the SECJul 15, 2024
FWP · Free writing prospectusJun 21, 2024
CORRESP · Letter to the SECJun 21, 2024
S-1/A · Registration statement, amendedJun 21, 2024
8-A12B · Registration of shares for listing on an exchangeJun 20, 2024
UPLOAD · Letter from the SECJun 18, 2024
FWP · Free writing prospectusJun 11, 2024
S-1/A · Registration statement, amendedJun 11, 2024
CORRESP · Letter to the SECJun 11, 2024
UPLOAD · Letter from the SECMay 31, 2024
CORRESP · Letter to the SECMay 24, 2024
S-1 · Registration statementMay 24, 2024
UPLOAD · Letter from the SECMay 20, 2024
DRS/A · Draft registration statement, amendedMay 13, 2024
DRSLTR · Letter to the SEC with a draftMay 10, 2024
UPLOAD · Letter from the SECMay 8, 2024
DRSLTR · Letter to the SEC with a draftApr 30, 2024
DRS/A · Draft registration statement, amendedApr 30, 2024
UPLOAD · Letter from the SECApr 19, 2024
DRSLTR · Letter to the SEC with a draftApr 9, 2024
DRS/A · Draft registration statement, amendedApr 9, 2024
UPLOAD · Letter from the SECApr 1, 2024
DRSLTR · Letter to the SEC with a draftMar 4, 2024
DRS · Draft registration statementMar 4, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Aug 13, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue0000
Research and development10.3M18.7M21.7M16.4M
Selling, general and administrative12.2M6.48M3.27M3.82M
Operating income-22.5M-25.2M-25.0M-20.2M
Depreciation and amortization25.2M25.0M20.2M
EBITDA0-10
Interest expense20.3K18.7K43.6K16.2K
Income before tax-22.2M-27.3M-24.7M-20.2M
Income tax8008000
Net income-22.2M-27.3M-24.7M-20.2M
Earnings per share, basic-1.06-3.26-17.24-1.34
Earnings per share, diluted-1.06-3.26-17.24

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents13.2M8.64M2.96M20.4M
Current assets13.6M9.21M3.00M20.5M
Total assets14.0M9.32M3.00M20.5M
Accounts payable1.52M1.92M3.42M2.13M
Current liabilities5.71M8.80M6.92M4.34M
Total debt405.0K405.0K405.0K
Total liabilities6.11M9.21M8.44M5.65M
Shareholders' equity7.92M104.2K-99.6M14.8M
Shares outstanding23.2M19.5M1.69M15.0M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-19.2M-21.8M-21.6M-17.8M
Capital spending0000
Free cash flow-19.2M-21.8M-21.6M-17.8M
Cash from financing23.7M27.5M4.13M19.3M
Share buybacks485.2K
Change in cash4.52M5.68M-17.5M1.46M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2026Big-stake noticeSEC
8-K · Current reportOct 30, 2026Current reportSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 29, 2026Insider tradeSEC
8-K · Current reportOct 28, 2026Material contractSEC
424B5 · ProspectusOct 28, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 27, 2026Other filingsSEC
All 193 filings
FilingDateTypeFiled with
S-1/A · Registration statement, amendedOct 19, 2026Offer documentSEC
S-1/A · Registration statement, amendedOct 14, 2026Offer documentSEC
FWP · Free writing prospectusOct 8, 2026Offer documentSEC
S-1 · Registration statementOct 6, 2026Offer documentSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportJul 17, 2026Current reportSEC
DRS · Draft registration statementJun 8, 2026Offer documentSEC
8-K · Current reportMay 22, 2026Meeting outcomeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMay 14, 2026Offer documentSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026Current reportSEC
3 · Initial statement of ownershipMay 6, 2026Insider tradeSEC
DEFA14A · Additional proxy materialMay 6, 2026Meeting noticeSEC
8-K · Current reportMay 6, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 22, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 9, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 6, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 6, 2026Meeting noticeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeDec 17, 2025Big-stake noticeSEC
144 · Notice of proposed saleDec 11, 2025Other filingsSEC
8-K · Current reportNov 28, 2025Material contractSEC
424B5 · ProspectusNov 28, 2025Offer documentSEC
8-K · Current reportNov 21, 2025Current reportSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportSep 10, 2025Material contractSEC
424B5 · ProspectusSep 10, 2025Offer documentSEC
424B5 · ProspectusSep 9, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 9, 2025Other filingsSEC
CORRESP · Letter to the SECSep 4, 2025Other filingsSEC
CORRESP · Letter to the SECSep 2, 2025Other filingsSEC
S-3 · Registration statementSep 2, 2025Offer documentSEC
UPLOAD · Letter from the SECAug 26, 2025Other filingsSEC
DRS · Draft registration statementAug 18, 2025Offer documentSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
EFFECT · Notice that a registration is effectiveAug 5, 2025Other filingsSEC
424B3 · ProspectusAug 4, 2025Offer documentSEC
CORRESP · Letter to the SECJul 31, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 31, 2025Other filingsSEC
S-1 · Registration statementJul 25, 2025Offer documentSEC
DJul 7, 2025Other filingsSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 30, 2025Big-stake noticeSEC
8-K · Current reportJun 26, 2025Material contractSEC
8-K · Current reportJun 5, 2025Current reportSEC
8-K · Current reportJun 2, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 27, 2025Big-stake noticeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
8-K · Current reportMay 23, 2025Meeting outcomeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMay 15, 2025Offer documentSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveApr 17, 2025Other filingsSEC
424B3 · ProspectusApr 16, 2025Offer documentSEC
CORRESP · Letter to the SECApr 14, 2025Other filingsSEC
DApr 10, 2025Other filingsSEC
DEFA14A · Additional proxy materialApr 8, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 8, 2025Meeting noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
UPLOAD · Letter from the SECApr 1, 2025Other filingsSEC
S-1 · Registration statementMar 28, 2025Offer documentSEC
8-K · Current reportMar 28, 2025Material contractSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportFeb 7, 2025Current reportSEC
8-K · Current reportDec 17, 2024Current reportSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024Current reportSEC
10-Q · Quarterly reportSep 24, 2024Quarterly reportSEC
SEC STAFF LETTERAug 27, 2024Other filingsSEC
4/A · Change in ownership, amendedAug 20, 2024Insider tradeSEC
4/A · Change in ownership, amendedAug 20, 2024Insider tradeSEC
4/A · Change in ownership, amendedAug 20, 2024Insider tradeSEC
SC 13D · Big-stake noticeAug 19, 2024Big-stake noticeSEC
8-K · Current reportAug 19, 2024Current reportSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
S-8 · Registration statement for employee plansAug 14, 2024Offer documentSEC
8-K · Current reportAug 14, 2024Management or board changeSEC
POS EXAug 13, 2024Other filingsSEC
424B4 · ProspectusAug 13, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 13, 2024Other filingsSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 12, 2024Insider tradeSEC
CERT · Exchange's certificate of listingAug 12, 2024Other filingsSEC
CORRESP · Letter to the SECAug 12, 2024Other filingsSEC
CORRESP · Letter to the SECAug 12, 2024Other filingsSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedAug 12, 2024Other filingsSEC
CORRESP · Letter to the SECAug 2, 2024Other filingsSEC
CORRESP · Letter to the SECAug 2, 2024Other filingsSEC
CORRESP · Letter to the SECJul 30, 2024Other filingsSEC
CORRESP · Letter to the SECJul 30, 2024Other filingsSEC
CORRESP · Letter to the SECJul 26, 2024Other filingsSEC
CORRESP · Letter to the SECJul 26, 2024Other filingsSEC
FWP · Free writing prospectusJul 23, 2024Offer documentSEC
S-1/A · Registration statement, amendedJul 23, 2024Offer documentSEC
CORRESP · Letter to the SECJul 19, 2024Other filingsSEC
CORRESP · Letter to the SECJul 19, 2024Other filingsSEC
FWP · Free writing prospectusJul 19, 2024Offer documentSEC
S-1/A · Registration statement, amendedJul 19, 2024Offer documentSEC
CORRESP · Letter to the SECJul 17, 2024Other filingsSEC
CORRESP · Letter to the SECJul 17, 2024Other filingsSEC
S-1/A · Registration statement, amendedJul 16, 2024Offer documentSEC
CORRESP · Letter to the SECJul 15, 2024Other filingsSEC
CORRESP · Letter to the SECJul 15, 2024Other filingsSEC
FWP · Free writing prospectusJun 21, 2024Offer documentSEC
CORRESP · Letter to the SECJun 21, 2024Other filingsSEC
S-1/A · Registration statement, amendedJun 21, 2024Offer documentSEC
8-A12B · Registration of shares for listing on an exchangeJun 20, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 18, 2024Other filingsSEC
FWP · Free writing prospectusJun 11, 2024Offer documentSEC
S-1/A · Registration statement, amendedJun 11, 2024Offer documentSEC
CORRESP · Letter to the SECJun 11, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 31, 2024Other filingsSEC
CORRESP · Letter to the SECMay 24, 2024Other filingsSEC
S-1 · Registration statementMay 24, 2024Offer documentSEC
UPLOAD · Letter from the SECMay 20, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftMay 10, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedMay 10, 2024Offer documentSEC
UPLOAD · Letter from the SECMay 8, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftApr 30, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedApr 30, 2024Offer documentSEC
UPLOAD · Letter from the SECApr 19, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftApr 9, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedApr 9, 2024Offer documentSEC
SEC STAFF LETTERApr 4, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 1, 2024Other filingsSEC
DMar 6, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftMar 4, 2024Other filingsSEC
DRS · Draft registration statementMar 4, 2024Offer documentSEC
D/ADec 15, 2022Other filingsSEC
DOct 19, 2022Other filingsSEC
DDec 10, 2020Other filingsSEC
D/ANov 14, 2019Other filingsSEC
DOct 15, 2019Other filingsSEC
DMay 13, 2019Other filingsSEC
DSep 12, 2018Other filingsSEC
DMar 20, 2017Other filingsSEC
DFeb 2, 2017Other filingsSEC
DOct 8, 2015Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Actuate Therapeutics, Inc.’s releases · as of Nov 13, 2026

Common shares
60,382,824
Fully diluted
60,382,824

Fully diluted

LineSharesAs of
Common shares60,382,824Nov 13, 2026

Share count over time

CountShares
Nov 13, 202660,382,824

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BIOS Capital Management, LP10M16.6%US$7.84MSep 30, 2026
Voss Capital, LP1.9M3.1%US$1.48MSep 30, 2026
Vanguard453K0.75%US$353KSep 30, 2026
Geode Capital104K0.17%US$81,333Sep 30, 2026
Texas Capital Bank Wealth Management Services Inc103K0.17%US$80,007Sep 30, 2026
Palogic Value Management, L.P.100K0.17%US$77,970Sep 30, 2026
Millennium90,1950.15%US$70,325Sep 30, 2026
ABS Investment Management LLC73,1860.12%US$57,063Sep 30, 2026
BlackRock66,9440.11%US$52,195Sep 30, 2026
Rock Creek Group LLC50,0000.08%US$38,985Sep 30, 2026
All 38 holders
HolderSharesOf the companyValueAs of
Sfmg, LLC50,0000.08%US$38,985Sep 30, 2026
HighTower Advisors, LLC36,4300.06%US$28,404Sep 30, 2026
Susquehanna25,0760.04%US$19,552Sep 30, 2026
Bridgeway Capital Management, LLC23,1060.04%US$18,016Sep 30, 2026
Empowered Funds, LLC23,1060.04%US$18,016Sep 30, 2026
State Street21,8500.04%US$17,036Sep 30, 2026
Northern Trust21,2200.04%US$16,545Sep 30, 2026
Gleason Group, Inc.19,0280.03%US$14,836Sep 30, 2026
Northwestern Mutual Wealth Management Co18,5180.03%US$14,438Sep 30, 2026
LPL Financial LLC11,9150.02%US$9,290Sep 30, 2026
Sowell Financial Services LLC10,9730.02%US$8,555Sep 30, 2026
Green Ridge Wealth Planning LLC10,0000.02%US$7,797Sep 30, 2026
FNY Investment Advisers, LLC8,2800.01%US$6,000Sep 30, 2026
Global Retirement Partners, LLC6,2500.01%US$4,873Sep 30, 2026
Nuveen6,1460.01%US$9,711Sep 30, 2026
Russell Investments Group, Ltd.5,932<0.01%US$4,625Sep 30, 2026
UBS2,707<0.01%US$2,111Sep 30, 2026
Wells Fargo2,440<0.01%US$1,902Sep 30, 2026
Morgan Stanley2,147<0.01%US$1,674Sep 30, 2026
RBC1,332<0.01%US$1,000Sep 30, 2026
Osaic Holdings, Inc.1,000<0.01%US$780Sep 30, 2026
BNP Paribas690<0.01%US$538Sep 30, 2026
Fidelity28<0.01%US$22Sep 30, 2026
IFP Advisors, Inc26<0.01%US$20Sep 30, 2026
Tower Research Capital LLC (TRC)17<0.01%US$13Sep 30, 2026
EverSource Wealth Advisors, LLC2<0.01%US$2Sep 30, 2026
Caitong International Asset Management Co., Ltd1<0.01%US$1Sep 30, 2026
Barclays1<0.01%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund287K0.48%US$440KJun 30, 2026
Vanguard Extended Market Index Fund106K0.18%US$162KJun 30, 2026
Fidelity Extended Market Index Fund51,9190.09%US$105KMay 31, 2026
Vanguard Russell 2000 Index Fund48,3950.08%US$97,758May 31, 2026
iShares Micro-Cap ETF38,2300.06%US$58,492Jun 30, 2026
Ultra-Small Company Market Fund23,4820.04%US$35,927Jun 30, 2026
Fidelity Nasdaq Composite Index Fund15,8850.03%US$32,088May 31, 2026
Fidelity Total Market Index Fund13,5910.02%US$27,454May 31, 2026
iShares Russell 2000 ETF13,2490.02%US$20,271Jun 30, 2026
Fidelity Series Total Market Index Fund12,2520.02%US$24,749May 31, 2026
All 30 holders
HolderSharesOf the companyValueAs of
Vanguard Russell 2000 Growth Index Fund8,8450.01%US$17,867May 31, 2026
iShares Russell 2000 Growth ETF5,506<0.01%US$8,424Jun 30, 2026
Small Cap Index Fund5,490<0.01%US$11,090May 31, 2026
Bridge Builder Small/Mid Cap Growth Fund1,738<0.01%US$2,659Jun 30, 2026
1290 VT Micro Cap Portfolio1,700<0.01%US$2,601Jun 30, 2026
Master Small Cap Index Series755<0.01%US$1,155Jun 30, 2026
ProShares Russell 2000 High Income ETF448<0.01%US$905May 31, 2026
EQ/2000 Managed Volatility Portfolio421<0.01%US$644Jun 30, 2026
ProShares UltraPro Russell2000351<0.01%US$709May 31, 2026
ProShares Ultra Russell2000350<0.01%US$707May 31, 2026
Small-Cap Index Portfolio239<0.01%US$366Jun 30, 2026
NVIT Small Cap Index Fund108<0.01%US$165Jun 30, 2026
BlackRock Small Cap Index V.I. Fund108<0.01%US$165Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio92<0.01%US$141Jun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio75<0.01%US$115Jun 30, 2026
EQ/Franklin Small Cap Value Managed Volatility Portfolio55<0.01%US$84Jun 30, 2026
Goldman Sachs Absolute Return Tracker Fund54<0.01%US$83Jun 30, 2026
PD Small-Cap Growth Index Portfolio46<0.01%US$70Jun 30, 2026
ProShares Hedge Replication ETF9<0.01%US$18May 31, 2026
ProShares Russell 2000 Dynamic Buffer ETF2<0.01%US$4May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Schmitt Daniel M
Director, Officer: President, CEO and Director
Buy140,844USD 0.35US$50,000Oct 28, 2026

Big stakes

StakeStakeSharesDateFiling
BIOS ADVISORS GP, LLC52.40%10MMay 22, 2025Schedule 13D
AARON G.L. FLETCHER49.80%10.3MJun 27, 2025Schedule 13D
Hexstone Capital LLC7.70%4.23MOct 27, 2026Schedule 13G
Voss Capital, LP7.70%1.81MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Aaron G.L. Fletcher
Other companies: Cognition Therapeutics, Inc. (Director · Since at least Oct 7, 2021); IN8bio, Inc. (Director · Aug 16, 2022 – Dec 12, 2022 · Past); TFF Pharmaceuticals Inc (Director · Oct 24, 2019 – Dec 29, 2022 · Past); Cue Biopharma, Inc. (Director · Oct 3, 2019 – Jan 3, 2023 · Past); SWK Holdings Corp (Director · Sep 3, 2019 – Dec 31, 2021 · Past)
Chairman · Since at least Aug 12, 2024
Roger Sawhney
Other companies: Adlai Nortye Group Ltd. (Independent Director · Since at least Mar 18, 2026); Arbutus Biopharma Corporation (Director · Since at least Aug 4, 2025); Alimera Sciences Inc (Director · Feb 25, 2023 – Feb 25, 2023 · Past); Omega Therapeutics Inc (Chief Financial Officer · Jul 29, 2021 – Mar 9, 2022 · Past)
Director · Since at least Aug 12, 2024
Jason Keyes
Other companies: BlossomHill Therapeutics, Inc. (Chief Financial Officer · Since at least Aug 6, 2026); Sesen Bio Inc (Director · May 3, 2021 – Jun 22, 2022 · Past); Equillium, Inc. (Chief Financial Officer · Dec 10, 2020 – Feb 14, 2025 · Past)
Director · Since at least Aug 12, 2024
Leslie W Kreis
Other companies: Cognition Therapeutics, Inc. (Director · Since at least Jun 10, 2022); IN8bio, Inc. (Director · Aug 16, 2022 – Dec 12, 2022 · Past); Lantern Pharma Inc. (Director · Jun 10, 2020 – Mar 17, 2022 · Past)
Director · Since at least Jun 27, 2025
Martin H Huber Jr
Other companies: Syndax Pharmaceuticals, Inc. (Director · Since at least Sep 15, 2021); Mersana Therapeutics Inc (President, CEO, Director · Since at least Jan 15, 2021); Xilio Therapeutics, Inc. (PRESIDENT AND HEAD OF R&D · Oct 21, 2021 – Aug 16, 2023 · Past)
Director · Since at least May 1, 2026
Todd Thomson
Other companies: ZOOZ Strategy Ltd. (Director · Since at least Mar 18, 2026); Dragonfly Energy Holdings Corp (Director · Aug 10, 2021 – Aug 10, 2021 · Past); Cordia Bancorp Inc (Director · Mar 29, 2013 – Aug 31, 2016 · Past)
Director · Since at least Aug 12, 2024
Paul Lytle
Other companies: Mosaic ImmunoEngineering Inc (EVP, Chief Financial Officer, Director · Since at least Aug 21, 2020); Avid Bioservices Inc (Chief Financial Officer · Feb 15, 2006 – Apr 28, 2017 · Past)
Chief Financial Officer · Since at least Aug 12, 2024
Amy Ronneberg
Other companies: Dianthus Therapeutics, Inc. (Director · Jun 20, 2018 – Jun 28, 2022 · Past)
Director · Since at least Aug 12, 2024
Andrew Paul Mazar
Other companies: Monopar Therapeutics Inc. (Chief Scientific Officer, Director · Jan 8, 2018 – Mar 31, 2022 · Past)
Chief Operating Officer · Since at least Aug 12, 2024
Dan Zabrowksi
Other companies: Apexigen Inc. (Director · Jul 29, 2022 – Aug 23, 2023 · Past)
Director · Since at least Aug 12, 2024
All 13 people
PersonSeat
Daniel M. SchmittPresident & Chief Executive Officer · Since at least Aug 12, 2024
Daniel ZabrowskiDirector · Since at least Nov 4, 2026
Martin HuberDirector · Since May 6, 2026

Open People

Log in to ask 6ix AI your own questions about Actuate Therapeutics, Inc.